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TNF-related apoptosis inducing ligand (TRAIL) expressions
were studied in primary human brain astrocytes in response
to pro-inflammatory cytokines. When astrocytes were treated
with IL-1 , TNF- or IFN- , TRAIL was induced in cultured β α γ
fetal astrocytes. In particular, IFN- induced the highest levels γ
of TRAIL in cultured astrocytes. When astrocytes were pre-
reated with IFN- , they induced apoptosis in TRAIL-sensitive γ
Peer cells. Our results suggest that IFN- modulates the γ
expression of TRAIL in astrocytes, which may enhance
cytotoxic sensitivity of infiltrating immune cells or brain cells
other than astrocytes during inflammation of brain.
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INTRODUCTION
In this study brain astrocytes were examined
from the standpoint of their cytotoxic effects.
During inflammation, significant astrocyte death
occurs after a period of reactive gliosis. Such
gliosis has been reported in Alzheimer's disease,
1
multiple sclerosis
2,3 and HIV infections.
4 TNF-
related apoptosis inducing ligand (TRAIL) is a
member of the death ligand/receptor pairs, and
acts independently of Fas mediated apoptosis.
5
TRAIL is consistently expressed in low-grade
astrocytomas, anaplastic astrocytomas, and glio-
blastomas.
6-8 However, little published informa-
tion is available about the relationship between
primary astrocytes and TRAIL, though we pre-
viously issued a report which demonstrated that
the mRNA of TRAIL is detectable in primary
astrocytes after stimulation with pro-inflamma-
tory cytokines.
9 When inflammation, tumor pro-
gression, or a degenerative disease occurs in the
CNS, lymphocytes infiltrate and secrete IFN- , γ
priming the immune reactions of astrocytes. We
previously reported that the full transcriptional
activity of STAT1 is manifested when the Ser727
is phosphorylated, and that this is dependent on
p38 MAP kinase in astrocytes.
10 Here, the ex-
pression of TRAIL in primary astrocytes induced
by IFN- , and TRAIL-mediated apoptosis were γ
addressed in an attempt to identify the func-
tional role of astrocytes in the apoptosis of brain
cells.
MATERIALS AND METHODS
Preparation of human brain astrocytes
Fetal astrocytes were isolated from a 25-week-
old human fetus. The brain samples were ob-
tained by therapeutic abortion. The use of tissue
samples was approved by the Institutional Review
Board. Astrocytes were cultured in 10% FCS
(Gibco BRL, Grand Island, NY)-DMEM (Gibco
BRL) containing 1% nonessential amino acids
(Sigma, St. Louis, MO) at 37 in 5% CO2. Primary
cultures were maintained for up to ten weeks.
Staining for glial fibrillary acidic protein (GFAP)
was done using anti-GFAP antibody (Pharmingen,
Human Brain Astrocytes Mediate TRAIL-mediated
Apoptosis after Treatment with IFN-γ
Jeonggi Lee, Jeon-Soo Shin, and In-Hong Choi
Department of Microbiology, Institute for Immunology and Immunological Diseases and Brain Korea 21 Project for Medical
Science, Seoul, Korea.
Received September 22, 2005
Accepted November 21, 2005
This work was supported by research grant from KOSEF
(RO1-2002-000-00210-0) and also by KOSEF through National
Core Research Center for Nanomedical Technology (R15-2004-024-
00000-0).
Reprint address: requests to Dr. In-Hong Choi, Department of
Microbiology, Yonsei University College of Medicine, 134 Shinchon-
dong, Seodaemun-gu, Seoul 120-752, Korea. Tel: 82-2-2228-1821,
Fax: 82-2-392-7088, E-mail: inhong@yumc.yonsei.ac.krTRAIL-Mediated Apoptosis in Astrocytes
Yonsei Med J Vol. 47, No. 3, 2006
San Diego, CA) to estimate the pure astrocyte
population, which revealed approximately 99% of
the cells were astrocytes. GFAP is the major com-
ponent of the intermediate filaments of astrocytes
and is commonly used as an astrocyte marker.
Staining with anti-HLA-DR antibody (Becton
Dickson, Franklin Lakes, NJ) was done to detect
microglias and activated astrocytes. Anti-GFAP or
anti-HLA-DR antibodies were conjugated with
FITC and used as recommended by the manufac-
ture.
RNase protection assay (RPA), RT-PCR and
southern blotting
For the induction of TRAIL, astrocytes were
cultured with IFN- (Genzyme, Cambridge, MA)
at a concentration of 250 U/mL or 500 U/mL for
8 or 24 hr. IL-1 (Genzyme) was treated at 100 β
U/mL, and TNF- (Genzyme) was treated at 750 α
U/mL for 8 hr for RNA preparation.
Total RNA was isolated using an RNeasy kit
(Qiagen, Santa Claris, CA). The level of TRAIL
mRNA was measured by RPA or RT-PCR. For
RPA, a RiboQuant multiprobe RNase protection
assay kit (Pharmingen) was used with 10 g of μ
total RNA. For RT-PCR, total RNA (1 g) was μ
used to synthesize cDNA using 0.1 O.D. of ran-
dom hexamer (Pharmacia, Uppsala, Sweden) and
200 U of M-MLV reverse transcriptase (Gibco
BRL). The TRAIL primers used were; forward:
5'-CCCAATGACGAAGAGAGTATGA-3'; reverse:
5'-GGAATAGATGTAGTAAAACCCT-3', and the
PCR conditions were as follows: denaturation at
94 for 30 sec, annealing at 59 for 30 sec and
extension at 72 for 30 sec. The PCR buffer con-
tained 10 mM Tris-HCl (pH 10), 2.0 mM MgCl2, 50
mM KCl with 1.25 U of Taq polymerase (Takara,
Tokyo, Japan). After 30 PCR cycles, an additional
extension at 72 for 10 min was performed for
all primers. -actin was used as the internal con β -
trol. Southern blotting was performed using the
TRAIL PCR product (100 ng) labeled using an
ECL kit (Amersham life Science, Piscataway, NJ)
and hybridized at 42 overnight.
Apoptosis assay
To evaluate the function of the induced TRAIL,
astrocytes pre-treated with IFN- for 24 hr were γ
reacted with Peer cells, which are sensitive to
TRAIL-mediated apoptosis.
11 Peer cells are of
lymphoid origin, and were maintained in suspen-
sion culture at 10% FCS-RPMI. Adherent astro-
cytes (effector cells) and floating Peer cells (target
cells) were reacted at E:T ratios of 1:1, 2:1, or 4:1.
Reactions were performed in 10% RPMI 1640 for
24 hr. Apoptotic cells were stained using Annexin
V-FITC (Trevigen, Gaithersburg, MD) and dead
cells using propidium iodide (Sigma, St. Louis,
MO). 1 × 10
5 cells were analyzed using a FACstar
(Becton Dickinson, San Jose, CA).
Western blotting
For western blotting, each protein (40 g) of μ
each whole cell homogenate was loaded on 12%
PAGE. Proteins were blotted onto a nitrocellulose
membrane (Amersham Pharmacia Biotech., Pis-
cataway, NJ) and incubated with 5 g/ml of μ
polyclonal mouse anti-human TRAIL antibody
(Pharmingen). After three washes in PBS conta-
ining 0.1% Tween 20, the membranes were in-
cubated with secondary peroxidase-conjugated
goat anti-mouse IgG (Jackson Immuno Research,
Baltimore, MD) for 1 hr, washed three times in
PBS containing 0.1% Tween 20, and developed
using an ECL system (Amersham Pharmacia
Biotech).
RESULTS
To evaluate TRAIL expression RPA was done
after treating brain astrocytes with IFN- , IL-1, or γ
TNF- . All of these cytokines induced TRAIL ex α -
pression, but the effect of IFN- was prominent γ
(Fig. 1A). RT-PCR and the subsequent southern
blot analysis of the RT-PCR product revealed that
TRAIL mRNA was present at a very low level
(Fig. 1B), and that IFN- increased the level of γ
TRAIL RNA. Western blotting showed TRAIL
protein was also increased by IFN- (Fig. 1C). γ
To determine the biological function of the
expressed TRAIL, primary astrocytes treated with
IFN- for 24 hr were reacted with Peer cells, γ
which have been reported to be TRAIL-sensitive
target cells. After reaction with astrocytes (effectorJeonggi Lee, et al.
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cells), floating Peer cells (target cells) were col-
lected carefully; the astrocytes remained adherent.
The Peer cells were then stained with annexin
V-FITC and propidium iodide. The percentages of
annexin V positive cells in the target Peer cell
population were 26.0% (E:T = 1:1), 41.4% (E:T =
2:1) or 43.9% (E:T = 4:1) after reaction with IFN-γ
treated astrocytes as compared with 3.9% (E:T =
1:1), 5.3% (E:T = 2:1), or 6.2% (E:T = 4:1) for IFN-γ
untreated astrocytes (Fig. 2). These results suggest
that induced TRAIL molecules on astrocytes are
functionally active and trigger apoptosis in proper
target cells. Treatment with IFN- for 24 hr did γ
not induce any apoptotic changes in primary as-
trocytes themselves (data not shown).
Fig. 1. Effect of IFN- on TRAIL expression in astrocytes. γ
2 × 10
5 astrocytes were pre-treated with IFN- (250 γ
U/mL) for 8 hr. (A) RPA was performed using 10 g total μ
RNA. IL-1 (100 U/mL) or TNF- (750 α U/mL) was treated
for 8 h. (B) TRAIL expression was determined by semi-
quantitative RT-PCR, and PCR product obtained was
subjected to southern blotting. -actin was used as an β
internal control. RT-PCR was performed in quadruplicate
and representative results are shown. (C) For western
blotting 40 g of each cell homogenate were loaded on a μ
12% PAGE. Proteins were blotted onto a nitrocellulose
membrane and incubated with 5 g/mL of polyclonal μ
mouse anti-human TRAIL antibody.
Fig. 2. Induction of apoptosis of Peer cells by astrocytes
treated with IFN- . 2 γ × 10
5 fetal brain astrocytes were
pre-treated with 250 U/mL of IFN- for 24 hr. Effector γ
cells (astrocytes) and target cells (Peer cells) were co-
cultured for 24 hr at an E:T ratio of 1:1, 2:1 or 4:1. After
collecting floating Peer cells, cell death was measured by
staining with annexin V-FITC and propidium iodide. Total
1 × 10
5 cells were analyzed by a flow cytometry. Astro-
cytes not treated with IFN- were used as control effector γ
cells. The assay was performed in quadruplicate and
representative results are shown.TRAIL-Mediated Apoptosis in Astrocytes
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DISCUSSION
Astrocytes have been reported to play a signi-
ficant role in the immune responses of the CNS.
12
They produce various cytokines 13 and express
the cell death mediated molecules Fas and
FasL.
3,9 Here, we report that the expression of
TRAIL can be induced in primary astrocytes by
IFN- treat γ ment. In this study, human astrocytes
expressed TRAIL at very low levels during
primary culture, however, IL-1 , TNF- , and β α
more significantly IFN- up-regulated TRAIL γ
expression. However, it has been suggested that
the human brain lacks TRAIL expression,
14 this
difference may reflect the in vivo status of TRAIL
expression. The low level of TRAIL expression
detected in control astrocytes in our study may
have been due to the slight activation of astro-
cytes during culture. However, we observed
TRAIL expression after IFN- treatment by γ
western blotting. In line with the results of the
present study, a recent report showed that TNF
and TRAIL do not induce apoptosis in reactive
astrocytes.
15 IFN- has been shown to increase γ
the expression of the TRAIL in human colon
cancer cell lines
16 and in human monocytes.
17
Moreover, the up-regulation of TRAIL expression
has been reported in NK cells of the liver,
spleen, and lungs, by the administration of IL-12,
a powerful inducer of IFN- production in NK γ
cells and NKT cells.
18 Moreover, TRAIL expres-
sion was not detected in the NK cells of IFN-γ
knock out mice.
18
In conclusion, the following were found in
human brain astrocytes; 1) TRAIL was expressed
at a very low level and this expression was in-
creased by IFN- stimulation, 2) astrocytes can γ
induce TRAIL-mediated apoptosis when they
were reacted with appropriate target cells. More-
over, the up-regulation of TRAIL may contribute
to immune privilege during fetal brain develop-
ment and to the apoptosis of neighboring cells
during pathological conditions.
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